Everett Harris & Co. CA Sells 7,344 Shares of Becton, Dickinson and Company $BDX

Everett Harris & Co. CA lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.3% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 549,492 shares of the medical instruments supplier’s stock after selling 7,344 shares during the period. Becton, Dickinson and Company makes up approximately 1.3% of Everett Harris & Co. CA’s holdings, making the stock its 16th biggest position. Everett Harris & Co. CA owned approximately 0.19% of Becton, Dickinson and Company worth $102,848,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Becton, Dickinson and Company by 15.4% in the second quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock worth $5,565,182,000 after purchasing an additional 4,305,947 shares during the last quarter. Norges Bank purchased a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth $653,377,000. First Eagle Investment Management LLC grew its holdings in shares of Becton, Dickinson and Company by 59.2% in the second quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after acquiring an additional 3,268,478 shares during the period. Massachusetts Financial Services Co. MA increased its position in Becton, Dickinson and Company by 24.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock valued at $1,466,613,000 after acquiring an additional 1,670,590 shares during the last quarter. Finally, Laurel Wealth Advisors LLC lifted its holdings in Becton, Dickinson and Company by 16,974.4% in the second quarter. Laurel Wealth Advisors LLC now owns 1,579,386 shares of the medical instruments supplier’s stock valued at $272,049,000 after acquiring an additional 1,570,136 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Down 0.3%

Shares of BDX stock opened at $201.27 on Friday. The company has a market capitalization of $57.34 billion, a price-to-earnings ratio of 34.52, a PEG ratio of 2.23 and a beta of 0.23. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The company’s fifty day moving average price is $198.32 and its 200-day moving average price is $191.05. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. During the same quarter in the prior year, the firm posted $3.81 EPS. Becton, Dickinson and Company’s quarterly revenue was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 72.04%.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock buyback program on Tuesday, January 27th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research reports. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Piper Sandler boosted their price objective on shares of Becton, Dickinson and Company from $190.00 to $205.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, Royal Bank Of Canada raised their target price on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 17th. Four investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $209.00.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares in the company, valued at $6,324,389.28. This represents a 0.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 2,680 shares of company stock worth $539,848. 0.40% of the stock is owned by insiders.

Key Stories Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Board approved an additional $10 million share repurchase authorization (company has completed ~ $250M YTD), which can modestly support EPS and signals management confidence despite the program’s small size relative to the ~$57B market cap. Becton, Dickinson and Company Board Declares Share Repurchase Plan
• Positive Sentiment: Board declared a quarterly dividend of $1.05 per share (payable Mar 31; ex‑dividend Mar 10), supporting income investors and reinforcing cash‑return discipline (annualized yield ~2.1%). BD Board Declares Dividend, Authorizes Repurchases
• Positive Sentiment: BD and Envetec demonstrated a closed‑loop recycling solution for common lab plastics — a sustainability initiative that could reduce waste/costs and support procurement wins with health systems focused on ESG. BD and Envetec Demonstrate Closed-Loop Recycling Solution
• Neutral Sentiment: Analyst roundup shows mixed but generally supportive views (several price target increases and a consensus “Hold”); useful for medium‑term sentiment but not an immediate catalyst. The Analyst Verdict: Becton Dickinson
• Neutral Sentiment: Valuation/valuation‑gap analysis pieces debate whether BDX’s P/E premium vs. cash‑flow value is justified — this framing can influence longer‑term positioning by value investors but doesn’t create immediate operational change. Is Becton Dickinson (BDX) Pricing Reflect The Gap Between Cash Flow Value And P/E Multiple
• Neutral Sentiment: BD is scheduled to release quarterly earnings soon; results and any guidance updates are the clearest near‑term catalysts that could cause volatility. BD to Release Quarterly Earnings
• Negative Sentiment: Insider selling: EVP Michael Feld sold 75 shares (~$15.2k) on Jan 26. The sale is very small relative to his holdings and the firm’s float, so impact is likely minimal but may be noted by short‑term traders. Michael Feld Sells 75 Shares

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.